Department of Urology, Zonguldak Bulent Ecevit University, Zonguldak, Turkey.
Department of Urology, Marmara University Istanbul Pendik Education and Research Hospital, Istanbul, Turkey.
Int J Clin Pract. 2021 Feb;75(2):e13857. doi: 10.1111/ijcp.13857. Epub 2020 Dec 4.
To investigate the effect of mirabegron 50 mg/daily for JJ stent-related symptoms after ureteroscopic stone surgery.
Medical records of 145 patients who were given a single daily oral dose of 50 mg of mirabegron for relieving stent-related symptoms were retrospectively analysed. Demographic and clinical data and stone parameters were recorded. All participants completed the Turkish version of the Ureter Symptom Score Questionnaire (USSQ-T) on the postoperative 7th day, and again after at least 3 weeks, before JJ stent removal. The severity of stent-related symptoms was statistically compared before and after the mirabegron treatment.
The mean urinary symptoms score decreased significantly from 30.87 ± 9.43 to 22.61 ± 6.78 (P < .0001), mean body pain score decreased significantly from 21.82 ± 11.22 to 14.03 ± 7.52 (P < .0001), mean work performance score decreased from 10.50 ± 8.61 to 7.02 ± 6.51 (P < .0001) and mean general health score decreased significantly from 15.43 ± 6.50 to 11.12 ± 3.70 (P < .0001). The mean sexual matters score significantly decreased from 3.88 ± 3.40 to 2.48 ± 2.03 (P < .0001), the additional problem score decreased from 9.31 ± 4.61 to 6.51 ± 2.83 (P < .0001) and the overall quality of life (QoL) score decreased from 5.18 ± 1.94 to 4.23 ± 1.71 after mirabegron use (P < .0001).
Daily use of 50 g of mirabegron significantly improved stent-related symptoms, sexual matters and quality of life.
研究米拉贝隆 50mg/天对输尿管镜碎石术后 JJ 支架相关症状的影响。
回顾性分析了 145 例接受 50mg 米拉贝隆单剂量口服以缓解支架相关症状的患者的病历。记录人口统计学和临床数据以及结石参数。所有参与者在术后第 7 天和 JJ 支架取出前至少 3 周时完成了土耳其版输尿管症状评分问卷（USSQ-T）。统计学比较米拉贝隆治疗前后支架相关症状的严重程度。
尿症状评分从 30.87±9.43 显著降至 22.61±6.78（P<.0001），体痛评分从 21.82±11.22 显著降至 14.03±7.52（P<.0001），工作表现评分从 10.50±8.61 降至 7.02±6.51（P<.0001），一般健康评分从 15.43±6.50 显著降至 11.12±3.70（P<.0001）。性问题评分从 3.88±3.40 显著降至 2.48±2.03（P<.0001），附加问题评分从 9.31±4.61 降至 6.51±2.83（P<.0001），整体生活质量（QoL）评分从 5.18±1.94 降至 4.23±1.71（P<.0001）。
每日使用 50mg 米拉贝隆可显著改善支架相关症状、性问题和生活质量。
